 ST. LOUIS, Feb. 24, 2021 GLOBE NEWSWIRE -- Stereotaxis NYSE: STXS, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitalization milestones. 